BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33626199)

  • 1. Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients.
    Fontova P; Colom H; Rigo-Bonnin R; Bestard O; Vidal-Alabró A; van Merendonk LN; Cerezo G; Polo C; Montero N; Melilli E; Manonelles A; Meneghini M; Coloma A; Cruzado JM; Torras J; Grinyó JM; Lloberas N
    Clin Pharmacol Ther; 2021 Jul; 110(1):238-247. PubMed ID: 33626199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.
    Zaltzman JS; Lai V; Schulz MZ; Moon KH; Cherney DZ
    Transpl Int; 2014 Dec; 27(12):1294-302. PubMed ID: 25160518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients.
    Allard M; Puszkiel A; Conti F; Chevillard L; Kamar N; Noé G; White-Koning M; Thomas-Schoemann A; Simon T; Vidal M; Calmus Y; Blanchet B
    Clin Ther; 2019 May; 41(5):882-896.e3. PubMed ID: 31003735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations.
    Fontova P; van Merendonk LN; Vidal-Alabró A; Rigo-Bonnin R; Cerezo G; van Oevelen S; Bestard O; Melilli E; Montero N; Coloma A; Manonelles A; Torras J; Cruzado JM; Grinyó JM; Colom H; Lloberas N
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients.
    Tan T; Bunnapradist S
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1175-1186. PubMed ID: 34459696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MeltDose Technology vs Once-Daily Prolonged Release Tacrolimus in De Novo Liver Transplant Recipients.
    Baccarani U; Velkoski J; Pravisani R; Adani GL; Lorenzin D; Cherchi V; Falzone B; Baraldo M; Risaliti A
    Transplant Proc; 2019 Nov; 51(9):2971-2973. PubMed ID: 31607620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation.
    David-Neto E; Romano P; Kamada Triboni AH; Ramos F; Agena F; Almeida Rezende Ebner P; Altona M; Galante NZ; Brambate Carvalhinho Lemos F
    Transplantation; 2017 Jun; 101(6):1365-1372. PubMed ID: 27482958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
    Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
    Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
    Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
    Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of calcineurin activity in peripheral blood mononuclear cells by ultra-high performance liquid chromatography-tandem mass spectrometry. Renal transplant recipients application (pharmacodynamic monitoring).
    Fontova P; Rigo-Bonnin R; Vidal-Alabró A; Cerezo G; Bestard O; Cruzado JM; Torras J; Grinyó JM; Lloberas N
    Clin Chim Acta; 2019 Aug; 495():287-293. PubMed ID: 31039337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of the conversion to MeltDose
    Sánchez Fructuoso A; Ruiz JC; Franco A; Diekmann F; Redondo D; Calviño J; Serra N; Aladrén MJ; Cigarrán S; Manonelles A; Ramos A; Gómez G; González Posada JM; Andrés A; Beneyto I; Muñiz AL; Perelló M; Lauzurica R
    Clin Transplant; 2020 Jan; 34(1):e13767. PubMed ID: 31815310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
    Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
    Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center, open-label, randomized cross-over study to evaluate the pharmacokinetics and bioavailability of once-daily prolonged-release formulations of tacrolimus in de novo liver transplant recipients.
    Herden U; Sterneck M; Buchholz BM; Achilles EG; Ott A; Fischer L
    Immun Inflamm Dis; 2021 Dec; 9(4):1771-1780. PubMed ID: 34559956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Envarsus in pediatric kidney transplant recipients - phase 1 pilot conversion study.
    Kim JJ; Lawless L; Marshall D; Maxted A; Lunn A; Mallik M; Williams A
    Pediatr Transplant; 2024 Mar; 28(2):e14703. PubMed ID: 38433334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients.
    David-Neto E; Agena F; Ramos F; Triboni AHK; Romano P; de Almeida Rezende Ebner P; Coelho V; Galante NZ; Lemos FBC
    Transplantation; 2017 Sep; 101(9):2133-2138. PubMed ID: 27798513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients.
    Stifft F; Undre N; van Hooff JP; Christiaans MH
    Ther Drug Monit; 2016 Aug; 38(4):456-62. PubMed ID: 27128604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.